![](https://easl.eu/wp-content/uploads/2023/04/Screenshot-2023-04-18-170311.png)
![](https://easl.eu/wp-content/uploads/2023/04/Screenshot-2023-04-18-170311.png)
EASL Policy Statement: risk-based surveillance for hepatocellular carcinoma among patients with cirrhosis
Geneva, 18 April 2023: This EASL Policy Statement about risk-based surveillance for hepatocellular carcinoma (HCC) among patients with cirrhosis demonstrates how risk-based surveillance has the potential to reduce not only deaths from HCC but also the costs of offering HCC surveillance.